o2h Ventures is pleased to announce that it has been shortlisted for the Growth Investor of the Year category at the One Nucleus Awards 2026.
The One Nucleus Awards recognise organisations contributing across the life sciences ecosystem, including research, investment, services and enabling support. The Growth Investor category highlights investors who help translate innovative science into developing companies.
As a biotech-specialist fund manager, o2h Ventures has supported more than 35 portfolio companies working across oncology, depression, dermatology, fibrosis, infectious disease and anti-ageing, all focused on improving human health.
Based in Cambridge, o2h Ventures works closely with founders from company creation through fundraising and development, combining capital with practical support, strategic input and community engagement to help build sustainable businesses addressing important unmet medical needs.
The nomination reflects o2h Ventures’ continued commitment to backing ambitious science and contributing to the wider biotech community alongside founders, partners and collaborators.
o2h Ventures congratulates all shortlisted organisations and looks forward to the awards ceremony on 19 March 2026.
Learn more about our EIS and SEIS funds at o2hventures.com/funds